Food Psych #316: The Truth About Those New Diet Drugs
Introduction:
Christy answers a listener question about Ozempic and other GLP-1 agonist drugs, and why we all should be extremely wary of any new diet drug being hailed as a "miracle."
Resources Mentioned
Subscribe to the weekly newsletter, Food Psych Weekly
Submit your questions for a chance to have them answered in the weekly newsletter
My online course, Intuitive Eating Fundamentals
My first book, Anti-Diet: Reclaim Your Time, Money, Well-Being, and Happiness Through Intuitive Eating
My upcoming book, The Wellness Trap: Break Free from Diet Culture, Disinformation, and Dubious Diagnoses and Find Your True Well-Being
My first piece about the new class of diet drugs, from 2021
Virginia Sole-Smith on the new AAP guidelines
Ragen Chastain on the new AAP guidelines
Content note: All of the links below contain weight-stigmatizing content and positive portrayals of diet drugs, so take care of yourself and maybe don’t click on anything if you’re feeling vulnerable.
People regain weight quickly once they stop these drugs
More than 17 percent of patients taking this class of drug developed masses of undigested or partially digested food in their GI tracts
Rare but serious side effects documented in clinical trials
Reports of gallbladder disease in patients on these drugs, with higher risks for people taking these drugs for weight loss than for diabetes, and for those taking them long-term as opposed to short-term.
Semaglutide and tirzepatide shown to cause thyroid tumors in rodents
Notorious diet drug Fen-Phen didn’t have a boxed warning, thanks to industry lobbying.
Belviq, another weight-loss drug that was pulled from the market in 2020 because of cancer risks, didn’t have one, either.
Article about Ozempic in which almost all sources have consulted for Novo Nordisk